JP2013535477A5 - - Google Patents

Download PDF

Info

Publication number
JP2013535477A5
JP2013535477A5 JP2013522132A JP2013522132A JP2013535477A5 JP 2013535477 A5 JP2013535477 A5 JP 2013535477A5 JP 2013522132 A JP2013522132 A JP 2013522132A JP 2013522132 A JP2013522132 A JP 2013522132A JP 2013535477 A5 JP2013535477 A5 JP 2013535477A5
Authority
JP
Japan
Prior art keywords
polyethylene glycol
noge
emissions
mpa
ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013522132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535477A (ja
JP5937593B2 (ja
Filing date
Publication date
Priority claimed from EP10008104A external-priority patent/EP2415460A1/de
Application filed filed Critical
Publication of JP2013535477A publication Critical patent/JP2013535477A/ja
Publication of JP2013535477A5 publication Critical patent/JP2013535477A5/ja
Application granted granted Critical
Publication of JP5937593B2 publication Critical patent/JP5937593B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013522132A 2010-08-03 2011-08-02 プレガバリンの経口投与剤形 Active JP5937593B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10008104.1 2010-08-03
EP10008104A EP2415460A1 (de) 2010-08-03 2010-08-03 Orale Darreichungsform von Pregabalin
PCT/EP2011/003873 WO2012016683A2 (en) 2010-08-03 2011-08-02 Oral dosage form of pregabalin

Publications (3)

Publication Number Publication Date
JP2013535477A JP2013535477A (ja) 2013-09-12
JP2013535477A5 true JP2013535477A5 (enExample) 2016-02-18
JP5937593B2 JP5937593B2 (ja) 2016-06-22

Family

ID=43216378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013522132A Active JP5937593B2 (ja) 2010-08-03 2011-08-02 プレガバリンの経口投与剤形

Country Status (6)

Country Link
US (1) US20130149253A1 (enExample)
EP (2) EP2415460A1 (enExample)
JP (1) JP5937593B2 (enExample)
KR (1) KR20140003376A (enExample)
CA (1) CA2806752A1 (enExample)
WO (1) WO2012016683A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013100873A1 (en) * 2011-12-19 2013-07-04 Mahmut Bilgic Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer)
WO2013109199A1 (en) * 2011-12-19 2013-07-25 Mahmut Bilgic Effervescent pharmaceutical formulations comprising pregabalin and vitamin b12
WO2013100874A1 (en) * 2011-12-19 2013-07-04 Mahmut Bilgic Effervescent pregablin formulation
MX2013001278A (es) * 2013-01-31 2014-07-30 Miguel Ángel García Pérez Composicion farmaceutica con un sistema bifasico de liberacion inmediata para el control de eventos convulsivos y del dolor.
WO2015031410A1 (en) * 2013-08-26 2015-03-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015114655A2 (en) * 2014-01-21 2015-08-06 Intas Pharmaceuticals Limited Modified release tablet of pregabalin
PL235144B1 (pl) * 2014-06-03 2020-06-01 Univ Medyczny Im Piastow Slaskich We Wroclawiu Sposób wytwarzania tabletki flotacyjnej o przedłużonym oddziaływaniu substancji leczniczych z błoną śluzową żołądka oraz kompozycja farmaceutyczna
CN104561442B (zh) * 2014-10-23 2017-05-31 东莞市佳平装饰材料有限公司 一种核电用347奥氏体不锈钢的制备方法
WO2016062182A1 (zh) * 2014-10-24 2016-04-28 江苏恒瑞医药股份有限公司 一种普瑞巴林缓释制剂
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
KR102039345B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
KR102039344B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 경구용 서방성 삼중정제
US20230320989A1 (en) * 2020-07-20 2023-10-12 Sichuan Haisco Pharmaceutical Co., Ltd. Sustained-release pharmaceutical formulation of fused tricyclic ?-amino acid derivative and preparation method therefor
CN112245404A (zh) * 2020-11-02 2021-01-22 成都晶富医药科技有限公司 一种普瑞巴林胶囊及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU94046105A (ru) 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
CA2343760A1 (en) * 1998-09-14 2000-03-23 Ranbaxy Laboratories Limited Orally administered controlled drug delivery system providing temporal and spatial control
CA2356829A1 (en) * 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
WO2007048223A2 (en) * 2005-10-25 2007-05-03 Pharmascience Inc. A gastric retention drug delivery system
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
NL2000281C2 (nl) * 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
EP1976503A2 (en) * 2005-12-29 2008-10-08 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
AU2007323018B2 (en) * 2006-09-04 2011-02-03 Panacea Biotec Limited Programmable buoyant delivery technology
TW200843732A (en) * 2006-12-21 2008-11-16 Xenoport Inc Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
US20110268666A1 (en) * 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
DK3045043T3 (da) * 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
KR101724024B1 (ko) * 2011-07-26 2017-04-06 주식회사유한양행 2상 방출-제어 시스템에 의한 프레가발린을 함유하는 서방성 정제

Similar Documents

Publication Publication Date Title
HRP20180965T1 (hr) Formulacija lijeka s produženim otpuštanjem
MX352476B (es) Carboximetilcelulosa nueva viscosidad alta y metodo de preparacion.
JP2016525572A5 (enExample)
EP2600849A4 (en) FILM-FORMING COMPOSITION FOR SOFT CAPSULES
WO2017155286A3 (ko) 2,5-퓨란디카르복시산 제조용 촉매 및 이 촉매를 이용한 2,5-퓨란디카르복시산의 제조방법
JP2015516240A5 (enExample)
CL2014000468A1 (es) Compuestos derivados del acido 2-oxo-6-(fenil/heteroaril)l-1,2-dihidropiridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para el alivio de una infeccion bacteriana.
WO2010084157A3 (en) Multifunctional stealth nanoparticles for biomedical use
NZ608239A (en) Aqueous drug delivery system comprising off - flavor masking agent
PL2475351T3 (pl) Nowy polimer w proszku, sposób jego wytwarzania i zastosowanie jako środka zagęszczającego
EP2749277A3 (en) Combination of glycopyrronium and vilanterol
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
JP2017520577A5 (enExample)
WO2010082220A3 (en) Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
CN109415361A (zh) 丙烯酸类衍生物及其制备方法和其在医药上的用途
UA117260C2 (uk) Лікарський препарат з відстроченим вивільненням
NZ603531A (en) Alcohol-resistant formulations
JP2013543913A5 (enExample)
EP3078377A3 (en) Nitazoxanide and tizoxanide as anti-viral agents
JP2016529286A5 (enExample)
WO2014198683A3 (en) Compositions comprising cross-linked hyaluronic acid and cyclodextrin
JP2014122166A5 (enExample)
JP2010521437A5 (enExample)
WO2007100822A3 (en) Fluvastatin sodium pharmaceutical compositions
WO2012117115A3 (de) Verwendung eines viskoelastischen fluids zur herstellung eines medizinproduktes für die chirurgische behandlung des auges